Intranasal Naloxone Dosing and Clinical Guidance
Dose Equivalency and Pharmacokinetics
- Intranasal naloxone administered at 2 mg per nostril (total 2–4 mg) yields systemic exposure comparable to 0.4–0.8 mg given intravenously, reflecting an approximate 50 % intranasal bioavailability. 1
- Practical dosing equivalency: intranasal doses of 2–4 mg approximate the clinical effect of 0.4–0.8 mg administered intravenously or intramuscularly. 1
Administration Protocols
Intranasal Route
- Standard initial dose: 2 mg per nostril (single‑dose spray containing 2 mg or 4 mg in 0.1 mL). Repeat dosing every 3–5 minutes if the clinical response is inadequate. 1, 2, 3
Intravenous Route
- Initial dose for suspected opioid overdose: 0.4–2 mg IV; repeat every 2–3 minutes if no response. Onset of action is rapid (1–2 minutes). 1, 4, 5
Intramuscular Route
- Initial dose: 0.4–2 mg IM; recommended when IV access is unavailable. 1
Clinical Goals and Safety
- Begin with the lowest effective naloxone dose to minimize precipitated opioid withdrawal while restoring adequate ventilation. 1, 2, 3
- The primary therapeutic goal is restoration of spontaneous breathing, not full return of consciousness. 1, 6
Re‑dosing and Monitoring
- Repeated naloxone dosing is often required, especially with long‑acting opioid exposures. 1
- After the last naloxone dose, patients should be observed for at least two hours to ensure sustained respiratory stability. 4, 5
Pediatric Dosing
- Intranasal naloxone for children < 5 years or < 20 kg: 0.1 mg/kg; for children ≥ 5 years or ≥ 20 kg: a fixed 2 mg dose. 7
- Naloxone should not be administered to neonates born to opioid‑dependent mothers due to the risk of severe withdrawal and seizures. 7